Allied Market Research
Loading...
Cart
0

Global HIV Drugs Market is Expected to Reach $36.49 Billion by 2027—Allied Market Research

 

Report Code : A01537

quote The growth of the global HIV drugs market is attributed to increase in number of patients suffering from HIV/AIDS. This factor is expected to drive the growth of the market. In addition, government initiatives to increase awareness among people have also boosted the market growth. quote

Ravi Telugunta
Lead Analyst, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “Global HIV Drugs Market by Medication Class and Region: Global Opportunity Analysis and Industry Forecast, 2020–2027," 

The global HIV drugs market accounted for $30.89 billion in 2019, and is expected to reach $36.49 billion by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Human immunodeficiency virus (HIV) is one of the most challenging infectious diseases that affected around 39.6 million people globally by the end of 2018, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). Antiretroviral Therapy (ART) drugs are used for the treatment of HIV as they prevent the growth of the HIV virus. 

The major factors that boost the growth of the market include increase in prevalence of HIV globally and rise in treatment & diagnosis rate. In addition, there is escalation in government initiatives to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Therefore, raising awareness through such government initiatives is expected to drive the HIV drugs market growth. However, stringent government regulations for the approval and commercialization of HIV drugs and side effects of HIV restrain the growth of the market.

As per the industry experts, long-term effect of COVID-19 outbreak is expected to be witnessed over the coming years. The outbreak has led to a situation of financial crisis in many countries. Moreover, in regions severely affected by COVID-19, HIV treatment procedures have been reduced to life or limb salvaging cases, owing to new government directives or hospital guidelines. Furthermore, all these factors are anticipated to impact the peripheral artery disease market as well in the future.

The global HIV drugs market is bifurcated on the basis of medication class and region. On the basis of medication class, the market is segmented into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors. In the medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection.

Region-wise, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. The North America region accounted for 48.40% of the overall HIV drugs market in 2019, and is expected to maintain this lead over the forecast period. The growth of the HIV drugs market in the region is attributed to the well-established healthcare system, higher diagnosis & treatment rate, government funding for R&D, and increase in adoption of advanced treatment options for the HIV-infected population. However, the Asia-Pacific and LAMEA HIV drugs markets are projected to grow faster, registering a CAGR of 4.4% & 3.6%, respectively, during the analysis period, owing to the prevalence of a large HIV-infected population in these regions, improvement in the healthcare infrastructure, and rise in the diagnosis & treatment rate of HIV. In addition, government initiatives to increase awareness among people have also boosted the HIV drugs market growth.

Key players in this market have adopted new product launch as the preferred strategy to expand their business. The key players profiled in this report include Boehringer Ingelheim International GmbH, Merck & Co., Inc., GalaxoSmithKline plc. AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, and Cipla Limited.

Key findings of the study 

  • North America accounted for 48.40% market share in 2019, and is expected to maintain this trend over the forecast period.
  • On the basis of medication class, the multi-class combination drugs segment is anticipated to grow at a CAGR of 4.1% from 2020 to 2027.
  • The Asia-Pacific HIV drugs market is estimated to grow at a CAGR of 4.4% during the forecast period.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote HIV Drugs Market By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2020–2027 quote

View Report
 
 
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Global HIV Drugs Market"
Purchase Enquiry